Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

Mysterios2 May. 15 at 5:01 PM

$IMMX Currently sitting at 52.53% Institutionally owned, 26.53% Insider owned. 41,914,405 shares held by these two buckets. Additionally 3 million plus shares short.

0 · Reply

LatinResearch May. 15 at 4:50 PM

$IMMX New 13G Janus Henderson 4.8m shares - 9.1% https://s3.amazonaws.com/sec.irpass.cc/2649/0001274173-26-000146.htm

1 · Reply

Mysterios2 May. 15 at 4:49 PM

$IMMX https://s3.amazonaws.com/sec.irpass.cc/2649/0001274173-26-000146.htm

0 · Reply

FetchDog May. 15 at 3:25 PM

$IMMX Added some at $9.61 today.

0 · Reply

Xan16 May. 15 at 2:19 PM

$IMMX Loaded more 11/20 $10 calls… That’s what you do on sell-off Fridays. You buy.

0 · Reply

CrossCountryStocks May. 15 at 2:10 PM

$IMMX getting under 9.50. You know what to do

0 · Reply

JamesonGummies May. 15 at 1:40 PM

$IMMX

0 · Reply

Cozartarded May. 15 at 1:40 AM

$IMMX

0 · Reply

InPlay1 May. 14 at 7:20 PM

$IMMX $IMRN to great stocks.

0 · Reply

Xan16 May. 14 at 7:04 PM

$IMMX 🎯🎯🎯

0 · Reply

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

2026-03-30T13:38:42.000Z - 6 weeks ago

Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon

MRK

$Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones$

Mar 30, 2026, 8:45 AM EDT - 6 weeks ago

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

2026-03-30T11:30:46.000Z - 6 weeks ago

Immix Biopharma price target raised to $15 from $14 at Mizuho

2026-03-27T10:16:27.000Z - 7 weeks ago

Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright

2026-03-25T08:55:10.000Z - 7 weeks ago

Immix Biopharma initiated with an Overweight at Morgan Stanley

2026-03-09T08:50:20.000Z - 2 months ago

Immix Biopharma initiated with an Outperform at Citizens

Mar 3, 2026, 8:45 AM EST - 2 months ago

Immix Biopharma to Participate in Upcoming Investor Conferences

2026-02-09T10:40:13.000Z - 3 months ago

Immix Biopharma initiated with an Outperform at Mizuho

2026-01-28T13:50:28.000Z - 3 months ago

Immix Biopharma receives FDA breakthrough therapy designation for NXC-201

Jan 28, 2026, 8:45 AM EST - 3 months ago

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

2026-01-09T22:30:15.000Z - 4 months ago

Immix Biopharma files $750M mixed securities shelf

Dec 9, 2025, 5:45 PM EST - 5 months ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2025-12-09T13:30:52.000Z - 5 months ago

Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright

2025-12-08T11:25:27.000Z - 5 months ago

Immix Biopharma 19.12M share Spot Secondary priced at $5.10

2025-12-08T01:50:12.000Z - 5 months ago

Immix Biopharma announces phase 2 NXC-201 results

Dec 7, 2025, 6:20 PM EST - 5 months ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

$At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Dec 7, 2025, 6:15 PM EST - 5 months ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

2025-11-12T13:50:43.000Z - 6 months ago

Immix Biopharma appoints Grabow as Chief Commercial Officer

Nov 12, 2025, 8:45 AM EST - 6 months ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 3, 2025, 8:45 AM EST - 6 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Oct 14, 2025, 8:45 AM EDT - 7 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 6, 2025, 4:05 PM EDT - 7 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

2025-10-06T12:15:52.000Z - 7 months ago

Immix Biopharma files to sell 6.85M shares of common stock for holders

Oct 1, 2025, 8:45 AM EDT - 8 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

$Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2$

Sep 18, 2025, 1:30 PM EDT - 8 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

2025-09-12T10:15:17.000Z - 8 months ago

Immix Biopharma price target raised to $8 from $7 at H.C. Wainwright

2025-09-11T13:35:30.000Z - 8 months ago

Immix Biopharma appoints Nancy Chang to board of directors

Sep 11, 2025, 9:15 AM EDT - 8 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

2025-09-08T20:20:08.000Z - 8 months ago

Immix Biopharma receives strategic investment from Goose Capital

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Aug 25, 2025, 9:30 AM EDT - 9 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 6, 2025, 12:30 PM EDT - 10 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

2025-07-11T13:40:51.000Z - 11 months ago

Immix Biopharma announces ‘class-leading’ safety profile for NXC-201

Jul 11, 2025, 9:36 AM EDT - 11 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

2025-07-07T13:40:34.000Z - 11 months ago

Immix Biopharma announces accelerated NEXICART-2 trial progress

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 11 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 6, 2025, 9:39 AM EDT - 1 year ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

2025-06-03T19:30:19.000Z - 1 year ago

Immix Biopharma files $13.45M common stock ATM offering

Jun 3, 2025, 3:00 PM EDT - 1 year ago

Immix Biopharma Transcript: Status Update

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 1 year ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 1 year ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 1 year ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 1 year ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Apr 23, 2025, 10:04 AM EDT - 1 year ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 1 year ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025, 9:34 AM EST - 1 year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 1 year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 2 years ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Apr 29, 2024, 9:39 AM EDT - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 18, 2024, 9:32 AM EDT - 2 years ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 2 years ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 20, 2024, 9:46 AM EDT - 2 years ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 5, 2024, 10:30 PM EST - 2 years ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 2 years ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Jan 24, 2024, 8:35 AM EST - 2 years ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Mysterios2 May. 15 at 5:01 PM

$IMMX Currently sitting at 52.53% Institutionally owned, 26.53% Insider owned. 41,914,405 shares held by these two buckets. Additionally 3 million plus shares short.

0 · Reply

LatinResearch May. 15 at 4:50 PM

$IMMX New 13G Janus Henderson 4.8m shares - 9.1% https://s3.amazonaws.com/sec.irpass.cc/2649/0001274173-26-000146.htm

1 · Reply

Mysterios2 May. 15 at 4:49 PM

$IMMX https://s3.amazonaws.com/sec.irpass.cc/2649/0001274173-26-000146.htm

0 · Reply

FetchDog May. 15 at 3:25 PM

$IMMX Added some at $9.61 today.

0 · Reply

Xan16 May. 15 at 2:19 PM

$IMMX Loaded more 11/20 $10 calls… That’s what you do on sell-off Fridays. You buy.

0 · Reply

CrossCountryStocks May. 15 at 2:10 PM

$IMMX getting under 9.50. You know what to do

0 · Reply

JamesonGummies May. 15 at 1:40 PM

$IMMX

0 · Reply

Cozartarded May. 15 at 1:40 AM

$IMMX

0 · Reply

InPlay1 May. 14 at 7:20 PM

$IMMX $IMRN to great stocks.

0 · Reply

Xan16 May. 14 at 7:04 PM

$IMMX 🎯🎯🎯

0 · Reply

bnglao24 May. 14 at 6:07 PM

$IMMX https://www.radcliffecardiology.com/webinars/novel-therapies-al-amyloidosis?language_content_entity=en When Heather speaks you better listen. 👀

1 · Reply

dcpanda May. 14 at 5:47 PM

$IMMX when is data read out? I can't wait!

1 · Reply

InPlay1 May. 14 at 5:02 PM

$IMMX target $24

1 · Reply

LatinResearch May. 14 at 3:59 PM

$IMMX You can see the algos working on Level 2, holding the SP down and accumulating. Float getting smaller everyday, 3m shorts, and time running with 30-patient data already outstanding. Too many catalysts in front of us and dirisking happening. I would not day trade this stock, it will jump suddenly soon. Patience & GLTA

0 · Reply